U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT

德克萨斯大学西南医学中心艾滋病临床试验单位（UTSMC）的科学重点 ACTU）将对艾滋病病毒感染的免疫发病机制和患者的免疫重建进行治疗 HAART。具体的专业领域包括成人胸腺在患者免疫重建中的作用， HAART，HIV特异性CD4+和CD8+ T细胞应答在控制HIV复制中的作用， 是否接受HIV感染治疗，以及免疫激活在HIV免疫发病机制中的作用。此外，本发明还提供了一种方法， UTSMC ACTU的研究人员在脂肪营养不良方面具有广泛的专业知识，他们将把这些知识带到以下研究中： 蛋白酶诱导的脂肪营养不良。考虑到临床和基础科学的优势，我们认为 拟议中的UTSMC ACTU将作为AACTG的使命的一个组成部分，开发新的和有效的 通过更好地了解H3V的发病机制， 诱发疾病。UTSMC ACTU的总体目标是为AACTG的使命做出贡献。这将 包括招募和保留适当的患者参加在 AACTG。这些患者将包括我们的临床设施所服务的不同人群的所有成员。更 重要的是，我们设想成为AACTG科学研究议程的积极参与者，并将做出贡献 它的知识基础和未来的方向。为了完成这一目标，UTSMC的具体目标是 ACTU将： (1)为艾滋病毒疾病研究议程作出贡献 (2)为艾滋病并发症研究议程做出贡献 (3)为免疫学研究议程做出贡献 (4)为其他研究项目做贡献 我们将通过临床研究（方案制定，患者 招募和保留）以及对招募的特征良好的患者进行深入科学研究的表现 AACTG的临床试验

The scientific focus of the University of Texas Southwestern Medical Center AIDS Clinical Trials Unit (UTSMC ACTU) will be on the immunopathogenesis of HIV infection and immune reconstitution of patients treated with HAART. Specific areas of expertise include the role of the adult thymus in immune reconstitution of patients on HAART, the role of HIV-specific CD4+ and CD8+ T cell responses in the control of HIV replication in patients who are, and are not, treated for HIV infection, and the role of immune activation in HIV immunopathogenesis. In addition, investigators at UTSMC ACTU have extensive expertise in lipodystrophies, which they will bring to the study of protease inhibitor-inducedlipodystrophy. Given the strengths in both clinical and basic science, we feel that the proposed UTSMC ACTU will serve as an integral part of the AACTG's mission to develop novel and effective treatments for HIV infection through a better understanding of the mechanisms underlying the pathogenesis of H3V- induced illness. The overall goal of the UTSMC ACTU will be to contribute to the mission of the AACTG. This will involve the enrolling and retention of appropriate patients into clinical trials developed within the framework of the AACTG. These patients will include all members of the diverse population served by our clinical facilities. More importantly, we envisionbeing active participants in the scientific research agenda of the AACTG, and will contribute substantially to its knowledge base and future direction. In order to complete this goal, the specific aims of the UTSMC ACTU will be: (1) To contribute to the HIV disease research agenda (2) To contribute to the complications of HIV disease research agenda (3) To contribute to the immunologyresearch agenda (4) To contributeto other research agendas We will accomplish these aims through the close interaction between clinical research (protocol development, patient recruitment and retention) and the performance of intensive scientific research on well-characterized patients enrolled in the clinical trials of the AACTG.